Roche on Monday revealed positive results from the EMBARK trial, showing that its gene therapy Elevidys has sustained benefits for individuals with Duchenne muscular dystrophy (DMD) over a two ...

Q4 2024 earnings showed 75% Y/Y revenue growth, driven by Elevidys, with net income tripling to $159.049 million and EPS of $1.50. Sarepta's pipeline includes gene therapies for LGMD, FSHD ...

Sarepta Therapeutics, Inc. SRPT reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks Consensus Estimate of $1.87. However, the reported figure was significantly ...

Shares of Solid Biosciences SLDB have rallied 59.9% in the past month. The stock price increase was mainly due to positive initial data, announced in mid-Feb, from the early to mid-stage study of ...

and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with duchenne with a confirmed mutation in the duchenne gene. The company is also ...

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...

The recent data from Sarepta’s Elevidys Phase III trial demonstrated significant improvements in primary and functional endpoints, which establishes the treatment’s efficacy and safety.

Solid claims the results, while early, suggest SGT-003 could be more potent than Sarepta Therapeutics’ Elevidys, the only approved Duchenne gene therapy. The company intends to discuss an ...

Elevidys (delandistrogene moxeparvovec) can now be used to treat both ambulatory and non-ambulatory boys aged four and above with DMD, a major expansion on its earlier accelerated approval with a ...

The data are the latest in a high-stakes race to create a better or safer gene therapy than Sarepta Therapeutics’ Elevidys, which was given broad approval last year amid intense debate at the ...